Evaluating a blood test for colorectal cancer diagnosis
Official title: Observational Cross-reactivity Study to Evaluate the Specificity of a Blood Test for Colorectal Cancer Diagnosis Based on Molecular Markers and Risk Factors Identified With Artificial Intelligence Tools
Run by Advanced Marker Discovery S.l. · NCT06889844 · Data updated 2026-11-12
This study is testing a blood test to see if it can accurately tell if people do not have colorectal cancer, helping to reduce incorrect positive results.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Advanced Marker Discovery S.l. Industry-sponsored |
| Drugs / interventions | chemotherapy |
| Locations | 5 sites (Málaga, Andalusia and 4 other locations) |
| Status | Recruiting |
| Started | April 17, 2023 |
| Main results expected | December 2025 |
| Study ends | December 2025 |
| Registry record updated | October 1, 2025 |
| Trial ID | NCT06889844 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who have been diagnosed with a single type of cancer or gastrointestinal disease, excluding colorectal cancer.
✕Probably not a fit
Patients with a history of colorectal cancer or related conditions, as well as those who have undergone certain cancer treatments, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to assess the false positive rate of a blood test that utilizes molecular biomarkers and risk factors for colorectal cancer diagnosis. A total of 250 patients with various cancers and gastrointestinal diseases will participate by donating blood samples as part of their routine medical care. The study will focus on understanding whether the blood test can accurately identify patients without colorectal cancer, thereby minimizing false positives in the diagnosis process.
Why it matters
Potential benefit: If successful, this study could lead to more accurate colorectal cancer diagnostics, reducing unnecessary anxiety and invasive procedures for patients.
How similar studies have gone: While there have been studies on blood tests for cancer diagnosis, this specific approach focusing on false positive rates in colorectal cancer is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients older than 18 years of age at the time of blood sample collection. * Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form. * Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease. Exclusion Criteria: * Patients who have received previous chemotherapy or radiotherapy. * In case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor. * Patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome. * Patients without appropriate staging or diagnosis. * Patients with hemolyzed plasma.
Where it's running
-
Hospitales HM de Malaga
Málaga, Andalusia, Spain Recruiting -
Hospital Centro Médico Asturias
Oviedo, Cantabria, Spain Recruiting -
Hospital Universitario de Ourense
Ourense, Galicia, Spain Recruiting -
Hospital Universitario HM Sanchinarro
Madrid, Madrid, Spain Recruiting -
MD Anderson Cancer Centre
Madrid, Madrid, Spain Active not recruiting
Study contacts
- Study coordinator: Marta Jimenez
- Email: mjimenez@amadix.com
- Phone: +34637899149
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.